Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

COVID-19 blood clot risk in MPN patients under microscope

NCT ID NCT04385160

Knowledge-focused Sponsor: FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 552 adults with myeloproliferative neoplasms (MPN) who also had COVID-19. Researchers wanted to see how often these patients developed blood clots, like pulmonary embolism. The goal was to understand what factors make COVID-19 worse for people with MPN.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand and manage COVID-19 risks in MPN patients.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all MPN patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

552 people

The number who actually took part.

Started

May 2020

Finished

Aug 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Myeloproliferative Neoplasm (Polycythemia Vera, Essential Polycythemia, Myelofibrosis) diagnosed with COVID-19 between 15 February 2020 and 15 February 2022

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Confirmed diagnosed of MPN according to WHO criteria * Diagnosis of COVID-19 based by the positivity of oropharyngeal swab performed between 15 February 2020 up to 15 February 2022 * Signed informed consent Exclusion Criteria: * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19 Myeloproliferative Disorders myeloproliferative neoplasm thrombotic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID Myeloproliferative neoplasm

Contacts and locations

Locations

  • A.O.U. Città della Salute e della Scienza di Torino

    Torino, 10126, Italy

  • A.S.O. SS. Antonio e Biagio e C.Arrigo di Alessandria

    Alessandria, 15121, Italy

  • AOU Ospedale Careggi

    Florence, 50134, Italy

  • ASST-Papa Giovanni XXIII

    Bergamo, 24127, Italy

  • ASST-Spedali Civili

    Brescia, 25123, Italy

  • Azienda Ospedaliero Universitaria Maggiore della Carità

    Novara, 28100, Italy

  • FEA Hematología Hospital Universitario de Móstoles

    Madrid, Spain

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, 20122, Italy

  • Guy's and St. Thomas' NHS Foundation Trust.

    London, United Kingdom

  • Hopital Saint-Louis

    Paris, France

  • Hospital 12 de octubre

    Madrid, Spain

  • Hospital Clínic De Barcelona

    Barcelona, Barcellona, Spain

  • Hospital Clínico San Carlos

    Madrid, Spain

  • Hospital Clínico Universitario

    Valencia, Spain

  • Hospital General de Elche

    Alicante, Spain

  • Hospital General de La Palma

    Breña Alta, Santa Cruz De Tenerife, Spain

  • Hospital Gregorio Marañón

    Madrid, Spain

  • Hospital Moncloa

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Hospital Universitario Infanta Leonor

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Hospital Universitario Príncipe de Asturias

    Alcalá de Henares, Madrid, Spain

  • Hospital Universitario de Burgos

    Burgos, Spain

  • Hospital Vall d'Hebron

    Barcelona, Spain

  • Hospital del Mar

    Barcelona, Barcellona, Spain

  • ICO Girona Hospital Josep Trueta Servei d'hematologia

    Girona, Spain

  • ICO L'Hospitalet - Hospital Moisès Broggi

    Sant Joan Despí, Barcelona, Spain

  • IRCCS Ospedale San Raffaele

    Milan, 20132, Italy

  • IRCCS Policlinico San Matteo

    Pavia, 27100, Italy

  • Institut Català d' Oncologia - Hospital Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • National Specialised Hospital for Active Treatment of Hematological Diseases

    Sofia, Bulgaria

  • New York-Presbyterian/Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Ospedale Policlinico "G.B. Rossi" Borgo Roma

    Verona, 37134, Italy

  • Ospedale San Bortolo

    Vicenza, 36100, Italy

  • Ospedale San Gerardo di Monza

    Monza, Monza Brianza, 20900, Italy

  • Policlinico S.Orsola-Malpighi

    Bologna, 40138, Italy

  • Policlinico Universitario Fondazione Agostino Gemelli

    Roma, 00168, Italy

  • Servicio de Hematología Hospital General Universitario de Albacete

    Albacete, Spain

  • Sobas Wroclaw Medical University ·

    Wroclaw, Poland

  • University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care, Johannes Wesling Medical Center

    Minden, Germany

  • University Hospital Halle, Department of Hematology/Oncology

    Halle, Saale, 06112, Germany

  • University Medical Center RWTH

    Aachen, Germany

  • University Medicine Greifswald - Hematology, Oncology, Stem Cell Transplantation and Palliative Care

    Greifswald, 17475, Germany

  • University hospital Dubrava-School of Medicine University of Zagreb

    Zagreb, Croatia

More trials for these conditions

Other studies related to the condition(s) this trial covers.